ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1068

Assessment of 10-Year Risk of Myocardial Infarction or Stroke in SLE

Michelle Petri1 and Laurence S Magder2, 1Johns Hopkins University School of Medicine, Baltimore, MD, 2University of Maryland School of Medicine, Baltimore, MD

Meeting: 2015 ACR/ARHP Annual Meeting

Date of first publication: September 29, 2015

Keywords: SLE and cardiovascular disease

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 8, 2015

Title: Systemic Lupus Erythematosus - Clinical Aspects and Treatment II: Patient-Reported Measures, Outcomes and Reporting

Session Type: ACR Concurrent Abstract Session

Session Time: 4:30PM-6:00PM

B

Background/Purpose: In 2013 the American College of Cardiology (ACC) and the American Heart Association (AHA) developed a new formula to estimate the 10-year risk of an adverse cardiovascular event based on traditional cardiovascular risk factors.  In contrast to previous formulae, this new formula focused on risk of “hard“ events of myocardial infarction or stroke.  Using a large cohort of patients with SLE, we derived a formula for estimating the 10-year risk of hard cardiovascular events (CVE) among patients with SLE based on both traditional and SLE-related risk factors, and compared our findings to the ACC/AHA risk estimates.

Methods: This analysis is based on data from the Hopkins Lupus Cohort since 1987.  A CVE was defined as the first occurrence of a stroke or myocardial infarction (MI).  Patients who had a CVE prior to cohort entry or within the first two years of cohort participation were exluded from the analysis.  There were 1513 patients included, 92% female, 54% Caucasian, 39% African-American, median age at baseline was 35 and median duration of follow-up was 8 years. To derive the score, risk factors were calculated based on variables measured in the first two years of cohort participation.  Cox Proportional Hazards models were constructed to determine the variables that affected the risk of a subsequent CVE. Using the results, a formula to calculate the risk of a CVE within the next 10 years was derived. 

Results: 100 CVE were observed:  63 strokes, 36 MI, and 1 diagnosed with both stroke and MI.   Table 1 shows the results of a multivariable Cox model used to estimate 10 year risk.

Table 1:  Association between predictors and risk of a CVD event among patients with SLE.

 

Hazard   Ratio (95% CI)

P-value

Age   (per decade)

1.3   (1.1, 1.5)

0.0050

Male   (vs. female)

1.5   (0.8, 2.8)

0.17

Systolic   Blood Pressure (per 10 mmHg)1

1.3   (1.1, 1.6)

0.0010

Cholesterol  (per 25 mg/dl)1

1.1   (1.0, 1.2)

0.11

Current   Smoking

1.6   (1.0, 2.6)

0.055

Diabetes

1.5   (0,9, 2.6)

0.12

SLEDAI   (per unit increase)1

1.1   (1.0, 1.2)

0.028

History   of Lupus Anticoagulant

2.2   (1.4, 3.3)

0.0003

Low   Mean C31

1.8   (1.1, 2.9)

0.027

1 Based on mean during the first two years of cohort participation.

Table 2 shows how the estimated 10-year risk for CVE based on this model compares to the risk from the ACC/AHA risk assessment tool for selected subgroups. 

Table 2:  Estimated 10-year risk based on our formula, and the ACC/AHA formula for selected subgroups.

Risk   Profile

Estimated   10-year risk based on our formula

Estimated   10-year risk based on 2013 ACC/AHA score1

White   Woman, age 40, SBP=120 (treated), Chol=150, HDL=40,

  No other risk factors

2.6%

0.7%

White   Woman, age 60, SBP=120 (treated), Chol=150, HDL=40, No other risk factors

4.2%

3.9%

White   Woman, age 60, SBP=120 (treated), Chol=150, HDL=40, Mean SLEDAI=3, No other   risk factors

6.9%

3.9%

White   Woman, age 60, SBP=120 (treated), Chol=150, HDL=40, Low C3, No other risk   factors

7.4%

3.9%

White   Woman, age 60, SBP=120 (treated), Chol=150, HDL=40, Hx of Lupus   Anticoagulant, No other risk factors

9.1%

3.9%

1 Calculated at   http://tools.cardiosource.org/ASCVD-Risk-Estimator/

Conclusion: Patients with SLE are generally at increased risk for myocardial infarction or stroke, especially at younger ages. The ACC/AHA score underestimates the true risk. The excess risk is highest among those with low complement, lupus anticoagulant, or high levels of disease activity.  Our risk assessment tool can be useful in guiding efforts to reduce traditional and SLE-related risk factors for “hard“ cardiovascular events among patients with SLE.


Disclosure: M. Petri, None; L. S. Magder, None.

To cite this abstract in AMA style:

Petri M, Magder LS. Assessment of 10-Year Risk of Myocardial Infarction or Stroke in SLE [abstract]. Arthritis Rheumatol. 2015; 67 (suppl 10). https://acrabstracts.org/abstract/assessment-of-10-year-risk-of-myocardial-infarction-or-stroke-in-sle/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2015 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/assessment-of-10-year-risk-of-myocardial-infarction-or-stroke-in-sle/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology